Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Jiangyang District, Luzhou, Sichuan, China.
Int J Clin Pract. 2023 Jan 24;2023:6733465. doi: 10.1155/2023/6733465. eCollection 2023.
Sepsis is a high-incidence disease and demands intensive care. Finding effective treatment is the key to cure sepsis. Studies have shown a lower level of vitamin C in patients with sepsis. Therefore, vitamin C supplementation has become one of the measures to treat sepsis. However, the clinical studies of vitamin C in the treatment of sepsis have been controversial. We performed a meta-analysis to evaluate vitamin C's efficacy and safety in the treatment of sepsis. We searched four electronic databases: PubMed, Embase, Web of Science, and the Cochrane Library, and two researchers independently screened 24 eligible RCTs published in English. Our review demonstrates that intravenous (IV) vitamin C might improve short-term mortality (RR, 0.82; 95% CI, 0.65-1.02; =0.07; and = 45%) and overall mortality (RR, 0.86; 95% CI, 0.74-1.01; =0.06; and = 51%) of patients with sepsis. Moreover, the SOFA score of patients with sepsis improved significantly after treatment with vitamin C for over 72 hours (RR, 0.26; 95% CI, 0.09-0.42; =0.002; and = 0%). The main results of our study were moderate-quality evidence. More high-quality, multicenter RCTs are needed to provide more substantial evidence on the efficacy and safety of IV vitamin C for sepsis.
脓毒症是一种高发病率的疾病,需要重症监护。寻找有效的治疗方法是治愈脓毒症的关键。研究表明,脓毒症患者的维生素 C 水平较低。因此,补充维生素 C 已成为治疗脓毒症的措施之一。然而,维生素 C 治疗脓毒症的临床研究一直存在争议。我们进行了一项荟萃分析,以评估维生素 C 在治疗脓毒症中的疗效和安全性。我们检索了四个电子数据库:PubMed、Embase、Web of Science 和 Cochrane Library,并由两名研究人员独立筛选了以英文发表的 24 项符合条件的 RCT。我们的综述表明,静脉注射(IV)维生素 C 可能改善脓毒症患者的短期死亡率(RR,0.82;95%CI,0.65-1.02;=0.07;和 = 45%)和总体死亡率(RR,0.86;95%CI,0.74-1.01;=0.06;和 = 51%)。此外,维生素 C 治疗超过 72 小时后,脓毒症患者的 SOFA 评分显著改善(RR,0.26;95%CI,0.09-0.42;=0.002;和 = 0%)。我们研究的主要结果是中等质量的证据。需要更多高质量、多中心的 RCT 来提供关于 IV 维生素 C 治疗脓毒症的疗效和安全性的更实质性证据。